Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,891 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,160 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06132191 | Expanded Access Use of Cemiplimab in Patients With Solid Tumors | approved for marketing | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Nov 20, 2025 | clinicaltrials |
| NCT04599712 | Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 13, 2025 |
| clinicaltrials |
| NCT04100694 | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | approved for marketing | — | — | Merus B.V.INDUSTRY | 0 | May 20, 2025 | clinicaltrials |
| NCT06064500 | Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer | approved for marketing | — | — | AmgenINDUSTRY | 4 | Mar 10, 2025 | clinicaltrials |
| NCT03906331 | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 13 | Jan 17, 2025 | clinicaltrials |
| NCT05733650 | Expanded Access Program for Epcoritamab | approved for marketing | — | — | GenmabINDUSTRY | 0 | May 25, 2023 | clinicaltrials |
| NCT04535557 | An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations | approved for marketing | — | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Sep 30, 2022 | clinicaltrials |
| NCT04829422 | Early Access Program of Lazertinib in Republic of Korea | approved for marketing | — | — | Yuhan CorporationINDUSTRY | 0 | Mar 3, 2022 | clinicaltrials |
| NCT04204928 | Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC | approved for marketing | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Aug 13, 2021 | clinicaltrials |
| NCT04504513 | Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer | approved for marketing | — | — | G1 Therapeutics, Inc.INDUSTRY | 0 | Mar 19, 2021 | clinicaltrials |
| NCT04291937 | A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA | approved for marketing | — | — | Jazz PharmaceuticalsINDUSTRY | 0 | Jun 19, 2020 | clinicaltrials |
| NCT00684385 | An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck | approved for marketing | — | — | AstraZenecaINDUSTRY | 4 | Mar 14, 2019 | clinicaltrials |
| NCT01931306 | Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC) | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00683306 | Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment | approved for marketing | — | — | AstraZenecaINDUSTRY | 19 | Sep 13, 2018 | clinicaltrials |
| NCT01649284 | Afatinib Expanded Access Program | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 30, 2016 | clinicaltrials |
| NCT01209650 | LUX Lung Special Access Scheme Australia Named Patient Use (NPU) | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 10, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Nov 20, 2025source: clinicaltrials